EP1631235A4 - COMPOSITIONS AND METHODS FOR MODULATING PROTEIN B7 EXPRESSION - Google Patents

COMPOSITIONS AND METHODS FOR MODULATING PROTEIN B7 EXPRESSION

Info

Publication number
EP1631235A4
EP1631235A4 EP04752823A EP04752823A EP1631235A4 EP 1631235 A4 EP1631235 A4 EP 1631235A4 EP 04752823 A EP04752823 A EP 04752823A EP 04752823 A EP04752823 A EP 04752823A EP 1631235 A4 EP1631235 A4 EP 1631235A4
Authority
EP
European Patent Office
Prior art keywords
expression
compositions
methods
modulating protein
modulating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04752823A
Other languages
German (de)
French (fr)
Other versions
EP1631235A2 (en
Inventor
Frank C Bennett
Timothy A Vickers
James G Karras
Susan M Freier
Brenda F Baker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ionis Pharmaceuticals Inc
Original Assignee
Isis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/444,206 external-priority patent/US20040023917A1/en
Application filed by Isis Pharmaceuticals Inc filed Critical Isis Pharmaceuticals Inc
Publication of EP1631235A2 publication Critical patent/EP1631235A2/en
Publication of EP1631235A4 publication Critical patent/EP1631235A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EP04752823A 2003-05-23 2004-05-19 COMPOSITIONS AND METHODS FOR MODULATING PROTEIN B7 EXPRESSION Withdrawn EP1631235A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10/444,206 US20040023917A1 (en) 1996-12-31 2003-05-23 Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US51061403P 2003-10-10 2003-10-10
US52040103P 2003-11-13 2003-11-13
US53729104P 2004-01-16 2004-01-16
PCT/US2004/015880 WO2005000202A2 (en) 2003-05-23 2004-05-19 Compositions and methods for the modulation of the expression of b7 protein

Publications (2)

Publication Number Publication Date
EP1631235A2 EP1631235A2 (en) 2006-03-08
EP1631235A4 true EP1631235A4 (en) 2008-05-21

Family

ID=33556628

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04752823A Withdrawn EP1631235A4 (en) 2003-05-23 2004-05-19 COMPOSITIONS AND METHODS FOR MODULATING PROTEIN B7 EXPRESSION

Country Status (2)

Country Link
EP (1) EP1631235A4 (en)
WO (1) WO2005000202A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1713332A4 (en) * 2004-01-23 2010-08-18 Avi Biopharma Inc ANTISENSE OLIGOMERS AND METHODS FOR INDUCING IMMUNE TOLERANCE AND IMMUNOSUPPRESSION
WO2016141236A1 (en) * 2015-03-03 2016-09-09 Ionis Pharmaceuticals, Inc. Compositions for modulating mecp2 expression

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000074687A1 (en) * 1999-06-04 2000-12-14 Isis Pharmaceuticals, Inc. Antisense modulation of b7 protein expression
WO2003083089A2 (en) * 2002-03-28 2003-10-09 Revivicor Inc. Tolerogenic antigen-presenting cells

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69834038D1 (en) * 1997-07-01 2006-05-18 Isis Pharmaceutical Inc COMPOSITIONS AND METHOD FOR THE ADMINISTRATION OF OLIGONUCLEOTIDES OVER THE DISHES

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6319906B1 (en) * 1996-12-31 2001-11-20 Isis Pharmaceuticals Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
WO2000074687A1 (en) * 1999-06-04 2000-12-14 Isis Pharmaceuticals, Inc. Antisense modulation of b7 protein expression
WO2003083089A2 (en) * 2002-03-28 2003-10-09 Revivicor Inc. Tolerogenic antigen-presenting cells

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; February 2001 (2001-02-01), QIAN S ET AL: "Administration of antisense oligodeoxyribonucleotides against mRNA of CD80 or CD86 prolongs survival of cardiac allografts by inhibition of CTL activity", Database accession no. PREV200100372589 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; 27 August 2003 (2003-08-27), LIANG XIAOYAN ET AL: "Administration of dendritic cells transduced with antisense oligodeoxyribonucleotides targeting CD80 or CD86 prolongs allograft survival.", Database accession no. NLM12973117 *
LIANG X ET AL: "PHENOTYPE AND ALLOSTIMULATORY FUNCTION OF DENDRITIC CELLS TREATED WITH ANTISENSE OLIGODEOXYRIBONUCLEOTIDES TARGETING CD80 OR CD86 MRNA", TRANSPLANTATION PROCEEDINGS, ORLANDO, FL, US, vol. 33, no. 1/02, 1 February 2001 (2001-02-01), pages 235, XP001036750, ISSN: 0041-1345 *
LIANG X ET AL: "Phenotype and allostimulatory function of dendritic cells treated with antisense oligodeoxyribonucleotides targeting CD80 or CD86 mRNA.", TRANSPLANTATION PROCEEDINGS 2001 FEB-MAR, vol. 33, no. 1-2, February 2001 (2001-02-01), pages 235, XP001036750, ISSN: 0041-1345 *
LIANG XIAOYAN ET AL: "Administration of dendritic cells transduced with antisense oligodeoxyribonucleotides targeting CD80 or CD86 prolongs allograft survival.", TRANSPLANTATION 27 AUG 2003, vol. 76, no. 4, 27 August 2003 (2003-08-27), pages 721 - 729, XP002474974, ISSN: 0041-1337 *
QIAN S ET AL: "Administration of antisense oligodeoxyribonucleotides against mRNA of CD80 or CD86 prolongs survival of cardiac allografts by inhibition of CTL activity.", TRANSPLANTATION PROCEEDINGS 2001 FEB-MAR, vol. 33, no. 1-2, February 2001 (2001-02-01), pages 551, XP002474973, ISSN: 0041-1345 *

Also Published As

Publication number Publication date
EP1631235A2 (en) 2006-03-08
WO2005000202A2 (en) 2005-01-06
WO2005000202A3 (en) 2006-01-19

Similar Documents

Publication Publication Date Title
EP1539218A4 (en) COMPOSITIONS AND METHODS FOR MODULATING LYMPHOCYTE ACTIVITY
EP1572944A4 (en) METHODS AND COMPOSITIONS FOR MODULATING XBP-1 ACTIVITY
EP1633307A4 (en) MODULATION OF SURVIVIN EXPRESSION
EP1687449A4 (en) ANTISENSE MODULATION OF THE EXPRESSION OF KINESIN 1 PROTEIN
EP1377587A4 (en) PROTEIN INHIBITORS PHOSPHATE
EP1633311A4 (en) COMPOSITIONS AND METHODS FOR MODULATING S-NITROSOGLUTATHION REDUCTASE
EP1317253A4 (en) BIOLOGICAL COMPONENT COMPRISING AN ARTIFICIAL MEMBRANE
DE50306941D1 (en) Disc prosthesis
EP1061800A4 (en) COMPOSITIONS AND METHODS MODULATING VASCULARIZATION
WO2004078995A3 (en) Methods of modulating and of identifying agents that modulate intracellular calcium
ATE381334T1 (en) 2,5-SUBSTITUTED TETRAHYDROISOCINOLINES FOR USE AS 5-HT6 MODULATORS
DK1252293T3 (en) Source of liver tissue
EP1677735A4 (en) METHODS AND COMPOSITIONS FOR MODULATING THE FUNCTION OF ADIPOCYTES
EP1638977A4 (en) SALINOSPORAMIDES AND METHODS OF USE
EP1251863A4 (en) 22 SEPARATE HUMAN PROTEINS
EP1187620A4 (en) ANTISENS MODULATION DE B7 PROTEIN EXPRESSION
EP1542721A4 (en) MODIFIED "S" ANTIBODIES
DE60316102D1 (en) One-component organopolysiloxane gel composition
ITMI20031061A1 (en) PROCEDURE AND DEVICE FOR MODULATION
EP1044211A4 (en) 36 HUMAN SECRETATED PROTEINS
EP1097199A4 (en) 71 HUMAN SECRETATED PROTEINS
ATE432699T1 (en) INDOL-5 SULFONAMIDE DERIVATIVES, THEIR PREPARATION AND USE AS 5-HT-6 MODULATORS
ATE362469T1 (en) 2,7-DISUBSTITUTEDINDOLES AND THEIR USE AS 5-HT6 MODULATORS
AU2003234198A8 (en) Novel genes, compositions, and methods for modulating the unfolded protein response
EP1124850A4 (en) 12 HUMAN SECRETATED PROTEINS

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

PUAK Availability of information related to the publication of the international search report

Free format text: ORIGINAL CODE: 0009015

17P Request for examination filed

Effective date: 20051219

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL HR LT LV MK

RIC1 Information provided on ipc code assigned before grant

Ipc: C07H 21/00 20060101ALI20060320BHEP

Ipc: C12N 5/00 20060101ALI20060320BHEP

Ipc: A61K 31/70 20060101AFI20060320BHEP

RIN1 Information on inventor provided before grant (corrected)

Inventor name: BAKER, BRENDA F.

Inventor name: FREIER, SUSAN, M.

Inventor name: KARRAS, JAMES, G.

Inventor name: VICKERS, TIMOTHY, A.

Inventor name: BENNETT, FRANK, C.

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 11/06 20060101ALI20080407BHEP

Ipc: A61K 48/00 20060101ALI20080407BHEP

Ipc: C12N 15/11 20060101AFI20080407BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20080417

17Q First examination report despatched

Effective date: 20100324

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ISIS PHARMACEUTICALS, INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20121201